Applied DNA Sciences(APDN) - 2023 Q1 - Quarterly Report

Financial Performance - Total revenues for the three months ended December 31, 2022, were $5,262,752, an increase of 26.4% compared to $4,165,706 for the same period in 2021[10]. - Gross profit for the three months ended December 31, 2022, was $2,377,683, significantly higher than $1,109,138 for the same period in 2021, reflecting improved operational efficiency[10]. - The net loss attributable to Applied DNA Sciences, Inc. for the three months ended December 31, 2022, was $3,843,372, a reduction from a net loss of $4,721,766 in the same period of the previous year, indicating a 18.5% improvement[10]. - Operating expenses for the three months ended December 31, 2022, were $3,596,661, down from $5,815,715 in the same period of 2021, reflecting a decrease of 38.1%[10]. - The company reported a net loss of $3,844,246 for the three months ended December 31, 2022, an improvement from a net loss of $4,720,911 in the same period of 2021[22]. - Net loss decreased by $876,665 or 19% to $3,844,246 for the three-month period ended December 31, 2022, compared to $4,720,911 for the same period in 2021[131]. Cash and Assets - Cash and cash equivalents decreased to $12,877,179 as of December 31, 2022, down from $15,215,285 as of September 30, 2022, representing a decline of 15.4%[8]. - Total assets decreased to $20,297,111 as of December 31, 2022, from $22,265,114 as of September 30, 2022, a reduction of 8.8%[8]. - Total current assets decreased to $18,332,352 as of December 31, 2022, down from $19,943,129 as of September 30, 2022, primarily due to a reduction in cash and cash equivalents[8]. - As of December 31, 2022, the Company had cash and cash equivalents of approximately $12.2 million in excess of the FDIC insurance limit[40]. Liabilities and Equity - Total liabilities increased to $11,138,670 as of December 31, 2022, compared to $9,356,175 as of September 30, 2022, marking a rise of 19.0%[8]. - The company has an accumulated deficit of $296,343,460 as of December 31, 2022, reflecting ongoing financial challenges[22]. - The balance of warrants outstanding decreased from 7,313,963 as of October 1, 2022, to 7,295,588 as of December 31, 2022, due to cancellations[55]. Revenue Segments - The company reported clinical laboratory service revenues of $4,514,295 for the three months ended December 31, 2022, compared to $3,200,122 for the same period in 2021, an increase of 40.9%[10]. - Clinical laboratory testing services revenue was $3,074,414 for the quarter, up from $1,873,722 year-over-year[34]. - The Therapeutic DNA Production segment generated revenues of $249,249, while MDx Testing Services contributed $4,514,295, and DNA Tagging and Security Products accounted for $499,208 in revenues for the same period[67]. Operational Efficiency - Selling, general and administrative expenses decreased by $2,110,262 or 45% to $2,625,357 for the three-month period ended December 31, 2022, mainly due to a reduction in stock-based compensation[126]. - Research and development expenses decreased by $108,792 or 10% to $971,304 for the three-month period ended December 31, 2022, primarily due to lower payroll and laboratory supply costs[127]. - The company is focusing on the commercialization of its MDx Testing Services, particularly its COVID-19 Testing Services, and advancing its research and development efforts[24]. Future Outlook - The company estimates it has sufficient cash to fund operations for the next twelve months, but may require additional funds for product development and operational losses[24][25]. - The company anticipates continued demand for its Therapeutic DNA Production Services and MDx Testing Services, which are critical to its growth strategy[83]. - The company is focusing on the development and commercialization of its Therapeutic DNA Production Services, particularly expanding its contract development and manufacturing operation (CDMO) for synthetic DNA[90]. Compliance and Internal Controls - The Company identified a material weakness in internal control over financial reporting related to complex financial instruments, specifically outstanding warrants and their tax impact[146]. - A remediation plan has been developed to address the material weakness, focusing on improving the review process for complex financial instruments[147]. - The Company is committed to maintaining a strong internal control environment and believes progress has been made towards remediation of the identified weakness[147].